Recent advances in the understanding of molecular underpinnings metastatic breast cancer have led to identification novel therapeutic targets. The latest update NCCN Guidelines for Breast Cancer reflects a rapidly evolving treatment landscape, highlighting growing importance combination therapies and personalized medicine managing estrogen-receptor (ER)–positive, HER2-positive, triple-negative ...
